<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485315</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2011-114</org_study_id>
    <nct_id>NCT01485315</nct_id>
  </id_info>
  <brief_title>Transfusion-requirements in Septic Shock Trial</brief_title>
  <acronym>TRISS</acronym>
  <official_title>Effects of Red Blood Cell Transfusion on Mortality and Morbidity in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scandinavian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with blood poisoning - sepsis - often receive blood transfusions in the intensive
      care unit. The evidence that blood transfusion leads to improved outcome is limited and the
      blood may be harmful to some of these patients. To bridge the gap between clinical practice
      and evidence, a large randomised clinical trial is needed to document the efficacy and safety
      of RBC transfusion in these very sick patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Septic patients often receive red blood cell (RBC) transfusions in the intensive
      care unit. The evidence that RBC transfusion leads to improved outcome is limited and the
      intervention may be harmful to some of these patients. In contrast, current guidelines
      recommend restrictive transfusion of RBC for critical ill patients without septic shock. To
      bridge the gap between clinical practice and evidence, a large randomised clinical trial is
      needed to document the efficacy and safety of RBC transfusion in patients with septic shock

      Design Pragmatic, multicenter, randomised, outcome assessment-blinded trial of patients with
      septic shock to RBC transfusion at haemoglobin (Hb) transfusion trigger of 7 g/dl (4.4 mM) or
      9 g/dl (5.6 mM), stratified by the presence of haematological malignancy and centre.

      Inclusion and exclusion criteria:

      To increase the validity of the trial inclusion criteria will be broad with few exclusions

      Outcome measures The outcome measures will mainly be patient-important but ICU- and hospital
      length of stay will also be assessed

      Trial size 2 x 500 patients will be needed to show a 9% absolute risk difference in 90-day
      mortality (baseline mortality of 45%, relative risk reduction 20% (from septic patients in
      the TRICC trial), alpha of 0.05 (two-sided) and a beta of 0.20 that is a power of 80%
      (1-beta).

      An interim-analysis will be performed after 500 patients. The Data Safety and Monitoring
      Board (DMSC) will recommend that the trial is stopped if a group-difference in 90-day
      mortality with p&lt;0.001.

      Time Line The first patient is expected to be randomised December 1st 2011 and the trial
      database is expected to be closed early 2014. The main manuscript will be submitted shortly
      thereafter.

      Funding The trial is publicly funded by the Danish Strategic Research Council
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 day</time_frame>
    <description>All cause 90 day mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistent organ failure</measure>
    <time_frame>Day 5</time_frame>
    <description>Defined as need for ventilation, vasopressor/inotrope infusion or renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent organ failure</measure>
    <time_frame>Day 14</time_frame>
    <description>Defined as need for ventilation, vasopressor/inotrope infusion or renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent organ failure</measure>
    <time_frame>Day 28</time_frame>
    <description>Defined as need for ventilation, vasopressor/inotrope infusion or renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anaphylactic/allergic reactions</measure>
    <time_frame>Followed up until ICU discharge; an expected average of one week</time_frame>
    <description>Defined by the clinician on the basis of mucocutaneous signs and symptoms (e.g. urticaria, pruritus, localised angio- oedema).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemolytic complications after transfusion of RBC</measure>
    <time_frame>Followed up until ICU discharge; an expected average of one week</time_frame>
    <description>Defined by the clinician on the basis of haemoglobinuria or increased free plasma haemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion associated acute lung injury (TRALI)</measure>
    <time_frame>Followed up until ICU discharge; an expected average of one week</time_frame>
    <description>TRALI defined as:
I. Acute or worsening hypoxaemia ((PaO2/FiO2 &lt; 40 (PaO2 in kPa) or &lt;300 (PaO2 in mmHg) regardless of PEEP) OR &gt; 50% relative increase in FiO2.
AND II. Occurrence within 6 hours after RBC transfusion AND III. Acute or worsening pulmonary infiltrates on frontal chest x-ray OR clinical signs of overt pulmonary oedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion associated circulatory overload (TACO)</measure>
    <time_frame>Followed up until ICU discharge; an expected average of one week</time_frame>
    <description>TACO defined as:
I. Acute or worsening hypoxaemia ((PaO2/FiO2 &lt; 40 (PaO2 in kPa) or &lt;300 (PaO2 in mmHg) regardless of PEEP) OR &gt; 50% relative increase in FiO2.
AND II. Occurrence within 6 hours after RBC transfusion AND III. Acute or worsening pulmonary infiltrates on frontal chest x-ray OR clinical signs of overt pulmonary oedema AND IV. Increased blood pressure AND VI. Positive fluid balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic events</measure>
    <time_frame>Followed up until ICU discharge; an expected average of one week</time_frame>
    <description>Defined as either myocardial, cerebral, intestinal or acute limb ischaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without life support</measure>
    <time_frame>90-days</time_frame>
    <description>Life support defined as need for ventilation, vasopressor/inotrope infusion or renal replacement therapy. Days alive without each of these interventions will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within the whole observation period</measure>
    <time_frame>One year after randomisation of the last patient</time_frame>
    <description>Mortality within the whole observation period reported at day 28, six-month and 1 year after randomisation of the last patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Physical and mental component summary scores of SF 36</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1005</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Liberal blood transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive blood transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion</intervention_name>
    <description>One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing</description>
    <arm_group_label>Liberal blood transfusion</arm_group_label>
    <other_name>Liberal red blood cell (RBC) transfusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion</intervention_name>
    <description>One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing</description>
    <arm_group_label>Restrictive blood transfusion</arm_group_label>
    <other_name>Restrictive red blood cell (RBC) transfusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient in the ICU AND

          -  Fulfil the criteria for septic shock AND

          -  Have haemoglobin of 9.0 g/dl (5.6 mM) or less AND

          -  Consent obtainable from patient or proxy or national law allows delayed consent

        Exclusion Criteria:

          -  Documented wish against transfusion OR

          -  Previous serious adverse reaction with blood product OR

          -  Acute coronary syndrome OR

          -  Life-threatening bleeding OR

          -  RBC transfusion during current ICU admission OR

          -  Withdrawal from active therapy or brain death OR

          -  Lack of informed consent (depending on national law) OR

          -  Acute burn injury regardless of degree and burn surface area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Perner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Intensive Care, Rigshospitalet / SCCTG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, NBG</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjørring Hospital</name>
      <address>
        <city>Hjørring</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horsens Hospital</name>
      <address>
        <city>Horsens</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Køge Hospital</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Næstved Hospital</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randers Hospital</name>
      <address>
        <city>Randers</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sønderborg Hospital</name>
      <address>
        <city>Sønderborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålborg University Hospital</name>
      <address>
        <city>Ålborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joensuu Hospital</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halmstad Hospital</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Växjö Hospital</name>
      <address>
        <city>Växjö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Holst LB, Haase N, Wetterslev J, Wernerman J, Aneman A, Guttormsen AB, Johansson PI, Karlsson S, Klemenzson G, Winding R, Nebrich L, Albeck C, Vang ML, Bülow HH, Elkjær JM, Nielsen JS, Kirkegaard P, Nibro H, Lindhardt A, Strange D, Thormar K, Poulsen LM, Berezowicz P, Bådstøløkken PM, Strand K, Cronhjort M, Haunstrup E, Rian O, Oldner A, Bendtsen A, Iversen S, Langva JÅ, Johansen RB, Nielsen N, Pettilä V, Reinikainen M, Keld D, Leivdal S, Breider JM, Tjäder I, Reiter N, Gøttrup U, White J, Wiis J, Andersen LH, Steensen M, Perner A. Transfusion requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus restrictive red blood cell transfusion in septic shock patients in the ICU: protocol for a randomised controlled trial. Trials. 2013 May 23;14:150. doi: 10.1186/1745-6215-14-150.</citation>
    <PMID>23702006</PMID>
  </reference>
  <results_reference>
    <citation>Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, Johansson PI, Aneman A, Vang ML, Winding R, Nebrich L, Nibro HL, Rasmussen BS, Lauridsen JR, Nielsen JS, Oldner A, Pettilä V, Cronhjort MB, Andersen LH, Pedersen UG, Reiter N, Wiis J, White JO, Russell L, Thornberg KJ, Hjortrup PB, Müller RG, Møller MH, Steensen M, Tjäder I, Kilsand K, Odeberg-Wernerman S, Sjøbø B, Bundgaard H, Thyø MA, Lodahl D, Mærkedahl R, Albeck C, Illum D, Kruse M, Winkel P, Perner A; TRISS Trial Group; Scandinavian Critical Care Trials Group. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014 Oct 9;371(15):1381-91. doi: 10.1056/NEJMoa1406617. Epub 2014 Oct 1.</citation>
    <PMID>25270275</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scandinavian Critical Care Trials Group</investigator_affiliation>
    <investigator_full_name>Anders Perner</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

